| The effect of morphine dependence on impulsive choice in rats C Harvey-Lewis, J Perdrizet, KBJ Franklin Psychopharmacology 223, 477-487, 2012 | 36 | 2012 |
| Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States L Huang, M Wasserman, L Grant, R Farkouh, V Snow, A Arguedas, ... Vaccine 40 (33), 4700-4708, 2022 | 24 | 2022 |
| Cost-effectiveness analysis of a multifactorial fall prevention intervention in older home care clients at risk for falling W Isaranuwatchai, J Perdrizet, M Markle-Reid, JS Hoch BMC geriatrics 17, 1-7, 2017 | 24 | 2017 |
| Clinical and economic burden of pneumococcal disease due to serotypes contained in current and investigational pneumococcal conjugate vaccines in children under five years of age MD Wasserman, J Perdrizet, L Grant, K Hayford, S Singh, P Saharia, ... Infectious Diseases and Therapy 10, 2701-2720, 2021 | 20 | 2021 |
| Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective D Shah, NA Risebrough, J Perdrizet, NN Iyer, C Gamble, T Dang-Tan ClinicoEconomics and Outcomes Research, 791-803, 2018 | 19 | 2018 |
| Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants J Perdrizet, CFS Santana, T Senna, RF Alexandre, R Sini de Almeida, ... Human Vaccines & Immunotherapeutics 17 (4), 1162-1172, 2021 | 15 | 2021 |
| A cost-utility analysis of magnetic resonance (MR) guided brachytherapy versus two-dimensional and computed tomography (CT) guided brachytherapy for locally advanced cervical … J Perdrizet, D D’Souza, J Skliarenko, M Ang, L Barbera, E Gutierrez, ... International Journal of Radiation Oncology* Biology* Physics 107 (3), 512-521, 2020 | 15 | 2020 |
| Pneumococcal vaccination in children: a systematic review and meta-analysis of cost-effectiveness studies MS Syeed, P Ghule, LM Le, SK Veettil, EK Horn, J Perdrizet, ... Value in Health 26 (4), 598-611, 2023 | 13 | 2023 |
| Retrospective impact analysis and cost-effectiveness of the pneumococcal conjugate vaccine infant program in Australia J Perdrizet, YS Lai, S Williams, VA Struwig, M Wasserman Infectious Diseases and Therapy 10, 507-520, 2021 | 12 | 2021 |
| Effect of correcting for gestational age at birth on population prevalence of early childhood undernutrition N Perumal, DE Roth, J Perdrizet, AJD Barros, IS Santos, A Matijasevich, ... Emerging themes in epidemiology 15, 1-13, 2018 | 11 | 2018 |
| Historical population-level impact of infant 13-valent pneumococcal conjugate vaccine (PCV13) national immunization programs on invasive pneumococcal disease in Australia … J Perdrizet, EK Horn, K Hayford, L Grant, R Barry, L Huang, C McDade, ... Infectious Diseases and Therapy 12 (5), 1351-1364, 2023 | 8 | 2023 |
| Effect of Correcting the Postnatal Age of Preterm-Born Children on Measures of Associations Between Infant Length-for-Age z Scores and Mid-Childhood Outcomes N Perumal, DE Roth, DC Cole, SH Zlotkin, J Perdrizet, AJD Barros, ... American Journal of Epidemiology 190 (3), 477-486, 2021 | 8 | 2021 |
| Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands M Wilson, C McDade, AT Beby-Heijtel, A Waterval-Overbeek, ... Infectious Diseases and Therapy 12 (7), 1809-1821, 2023 | 7 | 2023 |
| Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) versus lower-valent alternatives in Filipino infants J Perdrizet, EK Horn, W Nua, J Perez-Peralta, J Nailes, J Santos, ... Infectious Diseases and Therapy 10, 2625-2642, 2021 | 7 | 2021 |
| Delay discounting of oral morphine and sweetened juice rewards in dependent and non-dependent rats C Harvey-Lewis, J Perdrizet, KBJ Franklin Psychopharmacology 231, 2633-2645, 2014 | 7 | 2014 |
| Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population D Lytle, AG Grajales Beltrán, J Perdrizet, N Ait Yahia, A Cane, B Yarnoff, ... Human Vaccines & Immunotherapeutics 19 (2), 2257426, 2023 | 6 | 2023 |
| The broader impacts of otitis media and sequelae for informing economic evaluations of pneumococcal conjugate vaccines J Perdrizet, RA Farkouh, EK Horn, K Hayford, HL Sings, MD Wasserman Expert review of vaccines 21 (4), 499-511, 2022 | 5 | 2022 |
| Validation of a novel forecasting method for estimating the impact of switching pneumococcal conjugate programs: evidence from Belgium MR Wilson, CL McDade, JE Perdrizet, A Mignon, RA Farkouh, ... Infectious Diseases and Therapy 10, 1765-1778, 2021 | 5 | 2021 |
| Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants S Warren, M Barmpouni, V Kossyvaki, G Gourzoulidis, J Perdrizet Vaccines 11 (8), 1369, 2023 | 4 | 2023 |
| Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom M Wilson, A Lucas, D Mendes, A Vyse, B Mikudina, C Czudek, ... Vaccines 11 (7), 1168, 2023 | 4 | 2023 |
